Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Bladder cancer, Bowel (colorectal) cancer, Colon cancer, Rectal cancer, Stomach cancer, Transitional cell cancer, Womb (uterine or endometrial) cancer
Closed
Phase 2
This trial is looking at the chemotherapy drug methotrexate for people with a change to a gene called MSH2. It is for people who have
Bladder cancer, or cancer that stared in the lining of the urinary system )
Every cell contains DNA. This is the genetic information which controls how cells behave. In cancer cells, the DNA is changed or damaged. Cancers can have different types of changes in the DNA. One of these is when a called MSH2 is not working properly.
Doctors often use chemotherapy to treat cancer. But sometimes the cancer comes back after treatment and spreads elsewhere in the body.
Methotrexate is a chemotherapy drug that is used to treat some types of cancer. We know from research that methotrexate kills cancer cells when the MSH2 gene is not working properly. Researchers want to find out if it will help people with a faulty MSH2 gene who have cancer that has spread.
The aims of this trial are to
See how much methotrexate helps people in this situation
Learn more about the side effects
Recruitment start: 8 April 2009
Recruitment end: 31 August 2014
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor David Cunningham
Institute of Cancer Research (ICR)
The Royal Marsden NHS Foundation Trust
Last reviewed: 29 January 2015
CRUK internal database number: 2695
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
